{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:11:03Z","timestamp":1793823063797,"version":"4.6.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>O^6^-methylguanine\u2013DNA methyltransferase (MGMT) promoter methylation is a key predictive biomarker for temozolomide (TMZ) response in glioma. MGMT status is routinely assessed at diagnosis; however, its utility at recurrence remains incompletely characterized. We aimed to quantify MGMT methylation stability and assess the clinical relevance of reported status changes in recurrent glioma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We analyzed paired tumor samples from 426 patients with recurrent glioma in a large commercial molecular database containing quantitative methylation percentage and binary methylation status at two sample time points. A separate multi-institutional clinical cohort (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200927) with detailed treatment annotation was analyzed to explore associations between MGMT status at recurrence and treatment decision-making. Statistical analyses assessed quantitative methylation dynamics and time between samples as a surrogate for disease course.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      MGMT status remained unchanged in 84% of tumors across recurrence. 16% demonstrated a status change, commonly among tumors with low baseline methylation near classification thresholds. Longitudinal quantitative methylation changes were modest overall. Tumors that remained, gained, or lost hypermethylation demonstrated longer intervals between samples compared to consistently unmethylated tumors (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). In the clinical cohort, TMZ rechallenge was more frequently pursued in patients retaining hypermethylation at recurrence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MGMT promoter methylation is quantitatively stable in the majority of recurrent gliomas. Status changes predominantly occur in tumors with borderline methylation, highlighting the limitations of binary classification. These findings support routine reassessment of MGMT at recurrence and underscore the value of quantitative reporting to better inform therapeutic decision-making, particularly regarding TMZ rechallenge.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11060-026-05778-y","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:52:20Z","timestamp":1789545140000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Quantitative stability of MGMT promoter methylation in recurrent glioma and implications for temozolomide rechallenge"],"prefix":"10.1007","volume":"179","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9319-6846","authenticated-orcid":false,"given":"Henry","family":"Noren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Pelofsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna","family":"Suffren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mittelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Yohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aminah","family":"Twyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Febres-Aldana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arevik","family":"Abramyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Sertil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy S.","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan H.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morana","family":"Vojnic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"5778_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"5778_CR2","doi-asserted-by":"publisher","unstructured":"Szylberg M, Sokal P, Sledzinska P, Bebyn M, Krajewski S, Szylberg L, Szylberg A, Szylberg T, Krystkiewicz K, Birski M, Harat M, Wlodarski R, Furtak J (2022) MGMT Promoter methylation as a prognostic factor in primary glioblastoma: a single-institution observational study. Biomedicines 10. https:\/\/doi.org\/10.3390\/biomedicines10082030","DOI":"10.3390\/biomedicines10082030"},{"key":"5778_CR3","doi-asserted-by":"publisher","first-page":"274","DOI":"10.4274\/GULHANE.GALENOS.2021.1595","volume":"63","author":"WC Goh","year":"2021","unstructured":"Goh WC, Murali R, Shamsuddin S, Idris B, Idris Z, Ahmad F (2021) Potential of epigenetic biomarker O6-methylguanine-DNA methyltransferase gene in glioma. Gulhane Med J 63:274\u2013279. https:\/\/doi.org\/10.4274\/GULHANE.GALENOS.2021.1595","journal-title":"Gulhane Med J"},{"key":"5778_CR4","doi-asserted-by":"publisher","unstructured":"Kinslow CJ, Mercurio A, Kumar P, Rae AI, Siegelin MD, Grinband J, Taparra K, Upadhyayula PS, McKhann GM, Sisti MB, Bruce JN, Canoll PD, Iwamoto FM, Kachnic LA, Yu JB, Cheng SK, Wang TJC (2023) Association of MGMT promoter methylation with survival in low-grade and anaplastic gliomas after alkylating chemotherapy. JAMA Oncol 9(7):919\u2013927. https:\/\/doi.org\/10.1001\/jamaoncol.2023.0990","DOI":"10.1001\/jamaoncol.2023.0990"},{"key":"5778_CR5","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1093\/neuonc\/noab105","volume":"23","author":"S Brandner","year":"2021","unstructured":"Brandner S, McAleenan A, Kelly C, Spiga F, Cheng HY, Dawson S, Schmidt L, Faulkner CL, Wragg C, Jefferies S, Higgins JPT, Kurian KM (2021) MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review. Neuro Oncol 23:1457\u20131469. https:\/\/doi.org\/10.1093\/neuonc\/noab105","journal-title":"Neuro Oncol"},{"key":"5778_CR6","doi-asserted-by":"publisher","first-page":"CD013316","DOI":"10.1002\/14651858.CD013316.pub2","volume":"3","author":"A McAleenan","year":"2021","unstructured":"McAleenan A, Kelly C, Spiga F, Kernohan A, Cheng HY, Dawson S, Schmidt L, Robinson T, Brandner S, Faulkner CL, Wragg C, Jefferies S, Howell A, Vale L, Higgins JPT, Kurian KM (2021) Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide. Cochrane Database Syst Rev 3:CD013316. https:\/\/doi.org\/10.1002\/14651858.CD013316.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"5778_CR7","doi-asserted-by":"publisher","first-page":"6704","DOI":"10.1038\/s41598-018-25169-2","volume":"8","author":"AA Pandith","year":"2018","unstructured":"Pandith AA, Qasim I, Zahoor W, Shah P, Bhat AR, Sanadhya D, Shah ZA, Naikoo NA (2018) Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide). Sci Rep 8:6704. https:\/\/doi.org\/10.1038\/s41598-018-25169-2","journal-title":"Sci Rep"},{"key":"5778_CR8","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S1474-4422(10)70105-8","volume":"9","author":"M Jansen","year":"2010","unstructured":"Jansen M, Yip S, Louis DN (2010) Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol 9:717\u2013726. https:\/\/doi.org\/10.1016\/S1474-4422(10)70105-8","journal-title":"Lancet Neurol"},{"key":"5778_CR9","doi-asserted-by":"publisher","unstructured":"Brawanski KR, Sprung S, Freyschlag CF, Hoeftberger R, Strobel T, Haybaeck J, Thome C, Manzl C, Birkl-Toeglhofer AM (2023) Influence of MMR, MGMT promotor methylation and protein expression on overall and progression-free survival in primary glioblastoma patients treated with temozolomide. Int J Mol Sci 24. https:\/\/doi.org\/10.3390\/ijms24076184","DOI":"10.3390\/ijms24076184"},{"key":"5778_CR10","doi-asserted-by":"publisher","unstructured":"Feldheim J, Kessler AF, Monoranu CM, Ernestus RI, Lohr M, Hagemann C (2019) Changes of O(6)-methylguanine DNA methyltransferase (MGMT) promoter methylation in glioblastoma relapse-a meta-analysis type literature review. Cancers (Basel) 11. https:\/\/doi.org\/10.3390\/cancers11121837","DOI":"10.3390\/cancers11121837"},{"key":"5778_CR11","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1634\/theoncologist.2016-0254","volume":"22","author":"AA Brandes","year":"2017","unstructured":"Brandes AA, Franceschi E, Paccapelo A, Tallini G, De Biase D, Ghimenton C, Danieli D, Zunarelli E, Lanza G, Silini EM, Sturiale C, Volpin L, Servadei F, Talacchi A, Fioravanti A, Foschini MP, Bartolini S, Pession A, Ermani M (2017) Role of MGMT Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications. Oncologist 22:432\u2013437. https:\/\/doi.org\/10.1634\/theoncologist.2016-0254","journal-title":"Oncologist"},{"key":"5778_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/neuonc\/nop050","volume":"12","author":"AA Brandes","year":"2010","unstructured":"Brandes AA, Franceschi E, Tosoni A, Bartolini S, Bacci A, Agati R, Ghimenton C, Turazzi S, Talacchi A, Skrap M, Marucci G, Volpin L, Morandi L, Pizzolitto S, Gardiman M, Andreoli A, Calbucci F, Ermani M (2010) O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. Neuro Oncol 12:283\u2013288. https:\/\/doi.org\/10.1093\/neuonc\/nop050","journal-title":"Neuro Oncol"},{"key":"5778_CR13","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/ijc.26083","volume":"129","author":"J Felsberg","year":"2011","unstructured":"Felsberg J, Thon N, Eigenbrod S, Hentschel B, Sabel MC, Westphal M, Schackert G, Kreth FW, Pietsch T, Loffler M, Weller M, Reifenberger G, Tonn JC, German Glioma N (2011) Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer 129:659\u2013670. https:\/\/doi.org\/10.1002\/ijc.26083","journal-title":"Int J Cancer"},{"key":"5778_CR14","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3174\/ajnr.A7004","volume":"42","author":"HJ Choi","year":"2021","unstructured":"Choi HJ, Choi SH, You SH, Yoo RE, Kang KM, Yun TJ, Kim J, Sohn CH, Park CK, Park SH (2021) MGMT Promoter Methylation Status in Initial and Recurrent Glioblastoma: Correlation Study with DWI and DSC PWI Features. Am J neuroradiology: AJNR 42:853\u2013860. https:\/\/doi.org\/10.3174\/ajnr.A7004","journal-title":"Am J neuroradiology: AJNR"},{"key":"5778_CR15","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1158\/1078-0432.CCR-18-3181","volume":"25","author":"ME Hegi","year":"2019","unstructured":"Hegi ME, Genbrugge E, Gorlia T, Stupp R, Gilbert MR, Chinot OL, Nabors LB, Jones G, Van Criekinge W, Straub J, Weller M (2019) MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials. Clin Cancer Res 25:1809\u20131816. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3181","journal-title":"Clin Cancer Res"},{"key":"5778_CR16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11060-016-2116-y","volume":"128","author":"G Brigliadori","year":"2016","unstructured":"Brigliadori G, Foca F, Dall\u2019Agata M, Rengucci C, Melegari E, Cerasoli S, Amadori D, Calistri D, Faedi M (2016) Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma. J Neurooncol 128:333\u2013339. https:\/\/doi.org\/10.1007\/s11060-016-2116-y","journal-title":"J Neurooncol"},{"key":"5778_CR17","doi-asserted-by":"publisher","first-page":"533000","DOI":"10.3389\/fonc.2020.533000","volume":"10","author":"G Brigliadori","year":"2020","unstructured":"Brigliadori G, Goffredo G, Bartolini D, Tosatto L, Gurrieri L, Mercatali L, Ibrahim T (2020) Influence of Intratumor Heterogeneity on the Predictivity of MGMT Gene Promoter Methylation Status in Glioblastoma. Front Oncol 10:533000. https:\/\/doi.org\/10.3389\/fonc.2020.533000","journal-title":"Front Oncol"},{"key":"5778_CR18","doi-asserted-by":"publisher","unstructured":"Silva F, Di Domenico M, Caponio VCA, Perez-Sayans M, Camolesi GCV, Rojo-Alvarez LI, Ballini A, Garcia-Garcia A, Padin-Iruegas ME, Suarez-Penaranda JM (2024) Pyrosequencing analysis of O-6-methylguanine-DNA methyltransferase methylation at different cut-offs of positivity associated with treatment response and disease-specific survival in isocitrate dehydrogenase-wildtype grade 4 glioblastoma. Int J Mol Sci 25. https:\/\/doi.org\/10.3390\/ijms25010612","DOI":"10.3390\/ijms25010612"},{"key":"5778_CR19","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1158\/1078-0432.CCR-14-2737","volume":"21","author":"M Weller","year":"2015","unstructured":"Weller M, Tabatabai G, Kastner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bahr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkhah G, Meixensberger J, Vajkoczy P, Kollias S, Husing J, Reifenberger G, Wick W, Group DS (2015) MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Clin Cancer Res 21:2057\u20132064. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2737","journal-title":"Clin Cancer Res"},{"key":"5778_CR20","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1148\/radiol.2016152152","volume":"282","author":"C Kim","year":"2017","unstructured":"Kim C, Kim HS, Shim WH, Choi CG, Kim SJ, Kim JH (2017) Recurrent Glioblastoma: Combination of High Cerebral Blood Flow with MGMT Promoter Methylation Is Associated with Benefit from Low-Dose Temozolomide Rechallenge at First Recurrence. Radiology 282:212\u2013221. https:\/\/doi.org\/10.1148\/radiol.2016152152","journal-title":"Radiology"},{"key":"5778_CR21","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/neuonc\/noz011","volume":"21","author":"A Wenger","year":"2019","unstructured":"Wenger A, Ferreyra Vega S, Kling T, Bontell TO, Jakola AS, Caren H (2019) Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification. Neuro Oncol 21:616\u2013627. https:\/\/doi.org\/10.1093\/neuonc\/noz011","journal-title":"Neuro Oncol"},{"key":"5778_CR22","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1093\/jnen\/nlw052","volume":"75","author":"L Fontana","year":"2016","unstructured":"Fontana L, Tabano S, Bonaparte E, Marfia G, Pesenti C, Falcone R, Augello C, Carlessi N, Silipigni R, Guerneri S, Campanella R, Caroli M, Sirchia SM, Bosari S, Miozzo M (2016) MGMT-Methylated Alleles Are Distributed Heterogeneously Within Glioma Samples Irrespective of IDH Status and Chromosome 10q Deletion. J Neuropathol Exp Neurol 75:791\u2013800. https:\/\/doi.org\/10.1093\/jnen\/nlw052","journal-title":"J Neuropathol Exp Neurol"},{"key":"5778_CR23","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s11060-015-1738-9","volume":"122","author":"P Mur","year":"2015","unstructured":"Mur P, Rodriguez de Lope A, Diaz-Crespo FJ, Hernandez-Iglesias T, Ribalta T, Fiano C, Garcia JF, Rey JA, Mollejo M, Melendez B (2015) Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients. J Neurooncol 122:441\u2013450. https:\/\/doi.org\/10.1007\/s11060-015-1738-9","journal-title":"J Neurooncol"},{"key":"5778_CR24","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/S0140-6736(23)01054-1","volume":"402","author":"MJ van den Bent","year":"2023","unstructured":"van den Bent MJ, Geurts M, French PJ, Smits M, Capper D, Bromberg JEC, Chang SM (2023) Primary brain tumours in adults. Lancet 402:1564\u20131579. https:\/\/doi.org\/10.1016\/S0140-6736(23)01054-1","journal-title":"Lancet"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05778-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05778-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05778-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:01:50Z","timestamp":1792087310000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05778-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["5778"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05778-y","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"10 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Rutgers IRB and Northwell IRB.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prior consent obtained for use of all data analyzed in retrospective analysis.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Morana Vojnic: Consulting or Advisory role: AstraZeneca, Bristol-Myers Squibb, MJH Life Sciences, IDEOLogy Health, I3 Health, Janssen, Telix Pharmaceuticals.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"85"}}